Cytek Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CTKB$5.89+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (In thousands, except share and per share data) | September 30,2025 | December 31,2024 |
|---|---|---|
| (unaudited) | (audited) | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $93,281 | $98,716 |
| Restricted cash | — | 29 |
| Marketable securities | 168,453 | 179,145 |
| Trade accounts receivable, net | 56,632 | 60,588 |
| Inventories | 51,649 | 43,893 |
| Prepaid expenses and other current assets | 18,474 | 14,075 |
| Total current assets | 388,489 | 396,446 |
| Deferred income tax assets, noncurrent | 38,393 | 33,374 |
| Property and equipment, net | 18,046 | 17,962 |
| Operating lease right-of-use assets | 11,158 | 10,168 |
| Goodwill | 16,698 | 16,663 |
| Intangible assets, net | 17,676 | 20,128 |
| Other noncurrent assets | 4,459 | 4,759 |
| Total assets | $494,919 | $499,500 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Trade accounts payable | $7,632 | $5,529 |
| Legal settlement liability, current | 2,177 | 1,705 |
| Accrued expenses | 20,233 | 21,443 |
| Other current liabilities | 16,426 | 13,494 |
| Deferred revenue, current | 28,739 | 25,492 |
| Total current liabilities | 75,207 | 67,663 |
| Legal settlement liability, noncurrent | 8,158 | 9,036 |
| Deferred revenue, noncurrent | 16,315 | 16,098 |
| Operating lease liability, noncurrent | 13,494 | 7,552 |
| Long term debt | 655 | 1,050 |
| Other noncurrent liabilities | 2,519 | 2,364 |
| Total liabilities | $116,348 | $103,763 |
| Commitments and contingencies (Note 18) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 1,000,000,000 authorized shares as of September 30, 2025 and December 31, 2024, respectively; 127,864,830 and 129,205,901 issued and outstanding shares as of September 30, 2025 and December 31, 2024, respectively. | 128 | 129 |
| Additional paid-in capital | 435,284 | 430,791 |
| Accumulated deficit | (57,662) | (35,199) |
| Accumulated other comprehensive gain | 821 | 16 |
| Total stockholders’ equity | $378,571 | $395,737 |
| Total liabilities and stockholders’ equity | $494,919 | $499,500 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.